Summary by Moomoo AI
Theriva Biologics achieved target enrollment of 92 patients in its VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic ductal adenocarcinoma. The company is exploring potential expansion into a Phase 3 registrational trial. Theriva received manufacturing funding from the Spanish government and orphan/rare pediatric disease designations for VCN-01 in retinoblastoma.Q3 financial results show decreased R&D expenses of $2.7M vs $4.0M in Q3 2023, while G&A expenses increased to $2.3M from $212,000. The company recorded impairment charges of $1.3M for in-process R&D and $1.5M for goodwill. Cash and equivalents totaled $16.4M as of September 30, 2024.Theriva is advancing VCN-01, an oncolytic adenovirus for cancer treatment, as well as SYN-004 for preventing acute graft-versus-host disease in transplant patients. The company aims to expand the treatment landscape for hard-to-treat cancers like pancreatic cancer and retinoblastoma.
